| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SKYE | Common Stock | Award | $283K | +16.6M | +14.94% | $0.02 | 128M | Feb 22, 2023 | Direct | |
| transaction | SKYE | Common Stock | Award | $1.6M | +41.4M | +32.32% | $0.04 | 169M | Feb 22, 2023 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SKYE | Warrants | Other | $0 | +9.14M | $0.00 | 9.14M | Nov 10, 2022 | Common Stock | 9.14M | $0.15 | Direct | F1 | |
| transaction | SKYE | Warrants | Disposed to Issuer | $0 | -9.14M | -100% | $0.00* | 0 | Feb 22, 2023 | Common Stock | 9.14M | $0.02 | Direct | |
| transaction | SKYE | Warrants with Credit Facility of Oct 5, 2018 | Purchase | $0 | -2.5M | -100% | $0.00* | 0 | Feb 22, 2023 | Common Stock | 2.5M | $0.04 | Direct | |
| transaction | SKYE | Warrants with Credit Facility of Oct 5, 2018 - T2 | Disposed to Issuer | $0 | -2.5M | -100% | $0.00* | 0 | Feb 22, 2023 | Common Stock | 2.5M | $0.04 | Direct | F2 |
| transaction | SKYE | Warrants with Credit Facility of Oct 5, 2018 - T3 | Disposed to Issuer | $0 | -2.5M | -100% | $0.00* | 0 | Feb 22, 2023 | Common Stock | 2.5M | $0.04 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. ("Emerald"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock. |
| F2 | Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility. |